Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)

NCT01396083 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Visual Impairment
Macular Edema
Central Retinal Vein Occlusion

Interventions

DRUG: Ranibizumab
DRUG: Dexamethasone implant and sham injections

Sponsor

Novartis Pharmaceuticals